<DOC>
	<DOC>NCT00002236</DOC>
	<brief_summary>The purpose of this study is to see whether it is better to take delavirdine (DLV) plus indinavir (IDV) plus zidovudine (ZDV) twice a day or three times a day.</brief_summary>
	<brief_title>A Study to Find the Best Dosing Schedule for Delavirdine, Zidovudine, and Indinavir in HIV-Positive Patients</brief_title>
	<detailed_description>Patients are divided into 2 treatment groups; the groups are balanced with respect to viral load. Group A receives ZDV, DLV, and IDV 3 times daily. Group B receives ZDV, DLV, and IDV 2 times daily. Patients are evaluated for changes from baseline in viral load and CD4 cell count.</detailed_description>
	<mesh_term>HIV Infections</mesh_term>
	<mesh_term>Delavirdine</mesh_term>
	<mesh_term>Zidovudine</mesh_term>
	<mesh_term>Indinavir</mesh_term>
	<criteria>Inclusion Criteria You may be eligible for this study if you: Are HIVpositive. Have a viral load (level of HIV in the blood) of at least 20,000 copies/ml. Have a CD4 cell count of at least 50 cells/mm3. Are at least 14 years old (consent of parent or guardian is required if under 18). Exclusion Criteria You will not be eligible for this study if you: Have ever taken an antiHIV drug other than ZDV. Have taken ZDV for more than 1 month.</criteria>
	<gender>All</gender>
	<minimum_age>14 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2000</verification_date>
	<keyword>Drug Therapy, Combination</keyword>
	<keyword>Zidovudine</keyword>
	<keyword>Drug Administration Schedule</keyword>
	<keyword>HIV Protease Inhibitors</keyword>
	<keyword>CD4 Lymphocyte Count</keyword>
	<keyword>Indinavir</keyword>
	<keyword>Delavirdine</keyword>
	<keyword>Reverse Transcriptase Inhibitors</keyword>
	<keyword>Anti-HIV Agents</keyword>
	<keyword>Viral Load</keyword>
</DOC>